Key facts
- This page summarizes Mark Lawrence Rubinstein's Form 3 filing for ACHIEVE LIFE SCIENCES, INC. (ACHV).
- 0 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 12 Jan 2026, 08:10.
Mark Lawrence Rubinstein - 01 Jan 2026 Form 3 Insider Report for ACHIEVE LIFE SCIENCES, INC. (ACHV)
- Reporting relationship
- Chief Medical Officer
- Issuer ticker
- ACHV
- Reported as of
- 01 Jan 2026
- Net transaction value
- $0
- SEC form
- 3
- Accepted by SEC
- 12 Jan 2026, 08:10:03 UTC
- Prior SEC filing
- 30 Jan 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Sandra Thomson as attorney-in-fact for Mark Rubinstein
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Mark Lawrence Rubinstein filed Form 3 for ACHIEVE LIFE SCIENCES, INC. (ACHV) on 12 Jan 2026.
Change
- Previous filing in this sequence was filed on 30 Jan 2026.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reporting Owners (1)
CIK 0002103809
Primary reporting owner
Rubinstein Mark Lawrence
- Relationship
- Chief Medical Officer
- Address
- 22722 29TH DR. SE, SUITE 100, BOTHELL
- Signature
- /s/ Sandra Thomson as attorney-in-fact for Mark Rubinstein
- Signature date
- 12 Jan 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ACHV
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 39,600
- Date
- 01 Jan 2026
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ACHV
holding
Derivative
Stock Option (right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 01 Jan 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 47,000
- Exercise price
- $4.52
- Footnotes
- F1
ACHV
holding
Derivative
Stock Option (right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 01 Jan 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 50,000
- Exercise price
- $3.10
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
25% of the options became exercisable on September 30, 2025 and the remainder vest in thirty-six equal monthly installments thereafter.
Footnote F2
25% of the options become exercisable on October 7, 2026 and the remainder vest in thirty-six equal monthly installments thereafter.